非小细胞肺癌治疗的新靶点EML4ALK融合基.pdfVIP

538 · · 中国肺癌杂志2 0 1 1 年 6 月第 1 4卷第 6 期 Chin J Lung Cancer, June 2011, Vol.14, No.6 DOI: 10.3779/j.issn.1009-3419.2011.06.11 ·综 述· 非小细胞肺癌治疗的新靶点： EML4-ALK融合基因 王慧娟 袁静 综述 马智勇 审校 3 4 echinoderm microtubule-associated protein-like4, EML4 【摘要 】 年前棘皮动物微管相关类蛋白 （ ）与间变性 anaplastic lymphoma kinase, ALK non-small cell lung cancer, 淋巴瘤激酶（ ）融合基因被发现存在于部分非小细胞肺癌（ NSCLC ALK ）中。该融合基因常见于不吸烟的肺腺癌患者，有其独特的病理学特征，可以诱导肿瘤生成。 抑制剂能 够作用于该基因的下游信号传导通路并拮抗其促肿瘤生成活性。本文旨在介绍EML4-ALK基因的结构、功能、生物 学特征、检测方法及其在肺癌诊断治疗中的意义。 EML4-ALK融合基因；间变性淋巴瘤激酶；肺肿瘤 【关键词 】 R734.2 【中图分类号 】 A New Target in Non-small Cell Lung Cancer: EML4-ALK Fusion Gene Huijuan WANG, Jing YUAN, Zhiyong MA Department of Medical, Henan Tumor Hospital, Zhengzhou 450003, China Corresponding author: Zhiyong MA, E-mail: mazhiyong@csco.org.cn Abstract It was only 3 years ago that the fusion gene between echinoderm microtubule-associated protein-like4 【 】 (EML4) and anaplastic lymphoma kinase (ALK) has been identified in a subset of non-small cell lung cancer (NSCLC). EML4-ALK is most often detected in never smokers with lung adenocarcinoma and has unique pathologic features. EML4- ALK fusion gene is oncogenic, which could be suppressed by ALK-in